Article Text
Statistics from Altmetric.com
Review of: FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet 2019;393:265–74.
Key learning points
A large randomised trial of fluoxetine taken after a stroke found no statistically significant difference in functional status compared with placebo.
Fluoxetine resulted in a reduced rate of depression 6 months after stroke compared with placebo, but this effect was not sustained at 12 months.
Treatment with fluoxetine was associated with an increased risk of bone fractures at 6 months compared with placebo.
Fluoxetine did not improve functional status after acute stroke or cerebral ischaemia and was associated with a small increase in the risk of fractures.1
Overview
The Fluoxetine Or Control Under Supervision (FOCUS) trial was a large UK-based pragmatic multicentre parallel group double-blind randomised placebo-controlled trial that recruited …
Footnotes
Contributors DTB Team.
Provenance and peer review Commissioned; internally peer reviewed.